Aravive Inc

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aravive Biologics is a clinical-stage biotechnology company that focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.

Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position

Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Celsius Holdings

Salesforce

Chevron

Disney

Enphase Energy

JPMorgan Chase & Co

Coca-Cola

Merck

Northern Oil and Gas

Permian Basin Royalty Trust

Procter & Gamble

Walmart

Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +35.8% YTD. This week, the Momentum Gauges® turned negative for the first time in 2023 with an early negative test signal Feb. 3rd warning of deteriorating market conditions.

MDA Breakout Stocks Week 9 - March 2023: High-Frequency Gainers To Give You An Edge

Sangamo Therapeutics

Spruce Biosciences

Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies.

Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium

HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the achievement of full enrollment in the registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC). The global, randomized, double-blind, placebo-controlled Phase 3 AXLerate-OC trial is evaluating efficacy and tolerability of 15 mg/kg batiraxcept in combination with weekly paclitaxel versus placebo in combination with weekly paclitaxel. The trial was planned to enroll approximately 350 patients with platinum resistant, high grade serous ovarian cancer who received 1-4 prior lines of therapy at approximately 165 sites in the U.S. and Europe.

Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer

Aravive shareholders have been heavily diluted and suffered substantial losses in 2022. The company has struggled for cash, but now says it has funds to last at least until a pivotal data readout in 2023 for lead and only candidate Batiraxcept.

Aravive: Down But Not Out With Pivotal Ovarian Data Due In 2023

FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of 11.4 months in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of 11.4 months in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Piper 34th Annual Healthcare Conference being held on November 29 – December 1, 2022 in New York, NY.

Aravive To Participate in Piper's 34th Annual Healthcare Conference

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Blue Apron

Tattooed Chef

SHort squeze penny stocks to watch right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch Now

Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing Investors Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing Investors

Aravive Announces Approximately $41.5 Million Private Placement Financing

Milestone is Based on 3D Medicines' Initiation of the Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer in China Milestone is Based on 3D Medicines' Initiation of the Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer in China

Aravive Receives Third Development Milestone from 3D Medicines

HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the Cantor Fitzgerald Oncology & HemOnc Conference on September 28, 2022 at the Lotte New York Palace Hotel, New York, N.Y.

Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace Hotel, New York, N.Y.

Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) --  Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard as Chief Financial Officer, effective today. Vinay Shah has stepped down as CFO for personal reasons but will remain with the Company as an advisor to ensure a smooth transition.

Aravive Appoints Rudy Howard as Chief Financial Officer

HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated Phase 1b/2 ccRCC data at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 3-7, 2022 in Chicago. The abstract presents the updated response rate, landmark progression-free-survival data, and biomarker data.

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will present at the H.C. Wainwright Annual Global Investment Conference being held at the Fontainebleau Miami Beach Hotel May 23-26, 2022.

Aravive to Participate in H.C. Wainwright Global Investment Conference

HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of two poster abstracts at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held in-person on June 3-7, 2022 in Chicago, Illinois. Notably, abstract number 4511 was selected for an oral presentation as part of a Poster Discussion Session.

Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting

Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Aravive (ARAV) to Report a Decline in Earnings: What to Look Out for

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused institutional investor and Eshelman Ventures, LLC. In the offering, Aravive issued and sold an aggregate of 4,850,241 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,850,241 shares of common stock. The purchase price per share and accompanying warrant was $2.005 for the institutional investor and $2.325 for Eshelman Ventures, LLC.

Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Aravive Inc Stock (ARAV)